REGN
Regeneron Pharmaceuticals, Inc.Close $649.76EOD onlyThis page reflects REGN options positioning from the latest published market-close snapshot. Intraday price and contract changes are not displayed.
Historical consensus-supported lens with full content, report chain context, and metric rail.
Earnings Verdict
Earnings expected ~April 29 (inferred). IV elevated for May 1 expiration (49.3%), creating crush opportunity. Historical pattern shows strong EPS beats but limited data. Gamma pinning near $730-$750 suggests mean reversion pressure.
Regime Classification
Earnings Overview
Next earnings: 2026-04-29 (29 days)inferred
Expected moves:
- 5/01 (31d): ±$82.65 (10.7%)
IV Setup
Term structure: Clear kink at May 1 expiration (49.3% vs 44.3% on 4/24, 47.7% on 5/8)
Crush estimate: ~15 vol pts, back to ~34% (post-earnings typical IV)
Skew: Mixed flow with net premium positive but heavy put flow at $1000-$1020 strikes
Historical Context
Beat rate: 75% (3/4 quarters)
Avg move vs expected: Cannot calculate from provided data (no price moves)
Directional bias: 3/4 quarters beat EPS estimates
Key Levels
Flow Highlights
Massive put flow at $1000 ($1.65M) and $1020 ($1.95M) - net negative premium
Institutional hedging or downside protection for elevated strikes
Strong call flow at $610-$680 strikes ($400K-$800K net premium each)
Bullish positioning in lower strikes, possibly protective puts or defined risk plays
Strategies
Risk Assessment
What to Watch
Each report translates the same market-close options snapshot into a specific lens such as directional bias, premium-selling posture, flow quality, or earnings setup.
Reports are most useful for narrowing the playbook, surfacing entry and risk context, and deciding which raw data page to inspect next.
These are interpretation layers, not execution guarantees. Validate the setup against chain liquidity, expected move, and exposure before sizing risk.